PFE

$26.61

Market ClosedAs of Mar 16, 8:00 PM UTC

Pfizer Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHABBV

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$26.61
Potential Upside
1.1%
Whystock Fair Value$26.90
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$151.31B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.57
Beta
Defensive asset. Lower volatility than the S&P 500.
0.41
Div Yield
Strong income play. Yield provides a meaningful total return floor.
646.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
8.89%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.80

Recent News

Barrons.com
Mar 16, 2026

BioNTech Stock Is a Bargain. Why Its Recent Selloff Is a Buying Opportunity.

The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

GSK's RSV Vaccine Arexvy Wins FDA Nod for High-Risk Younger Adults

GSK secures FDA approval to expand Arexvy's use to high-risk adults aged 18-49 years, broadening access as the company pushes wider global adoption.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 16, 2026

Pfizer Trials Highlight Effort To Broaden Future Revenue And Defend Franchises

Pfizer (NYSE:PFE) has started a Phase 1 trial of a new tafamidis tablet formulation aimed at improving manufacturing flexibility and cost-efficiency. The company has initiated a Phase 2 pediatric trial of etrasimod in ulcerative colitis and a Phase 1 trial for a next generation oncology candidate. Pfizer has completed a Phase 2 study of its multivalent pneumococcal vaccine candidate PG4, with data analysis underway. These updates provide a fresh look at how Pfizer, best known recently for...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 16, 2026

Is Zoetis Inc. (ZTS) A Good Stock To Buy Now?

Is ZTS a good stock to buy now? We came across a bullish thesis on Zoetis Inc. on Rebound Capital’s Substack. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.’s share was trading at $131.10 as of February 27th. ZTS’s trailing and forward P/E were 21.78 and 19.08 respectively according to Yahoo Finance. Zoetis […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 16, 2026

Is Pfizer Inc. (PFE) A Good Stock To Buy Now?

Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $26.81 as of March 9th. PFE’s trailing and forward P/E were 19.89 and 9.14, respectively according to Yahoo Finance. Pfizer Inc. […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.